Celgene (NSDQ:CELG) said today it inked a collaborative deal with TriNetX to develop advanced clinical trial design for Celgene’s next-gen therapeutic programs.
Through the deal, Celgene will be able to access medical data from electronic medical records through TriNetX’s proprietary network of healthcare institutions, the companies said.
“TriNetX represents the future of a data-driven approach to clinical trial design and research. This collaboration is an important part of the innovations we have been making at Celgene to realize the power of data analytics within our clinical research organization,” Celgene global clinical research development and operations senior veep Jay Kaminski said in a press release.
TriNetX said its system can be used to analyze patient populations with search criteria spanning multiple longitudinal data points in real time.
Each data point can be traced to healthcare providers who have the ability to identify individual patients and allow for the creation of virtual patient cohorts.
“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away. Through our network, healthcare providers, pharma and contract research organizations can create strategic partnerships to improve clinical research and patient care, and we are honored to have Celgene as part of our network. We see this collaboration as a win-win for Celgene, TriNetX, our member institutions, and ultimately patients,” TriNetX CEO Gadi Lachman said in a prepared statement.
